<DOC>
	<DOC>NCT00311740</DOC>
	<brief_summary>The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combination treatments are safe and well tolerated. The study aims to establish a dose response relationship for both monotherapies and the combinations. This study is being conducted in Japan.</brief_summary>
	<brief_title>A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Valsartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Essential hypertension measured by mercury sphygmomanometer Outpatients Secondary hypertension or suspected of having secondary hypertension. A history of malignant hypertension Severe hypertension Significant heart, renal, hepatic diseases or significant cerebrovascular disorder Gout Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypertension,</keyword>
	<keyword>Valsartan,</keyword>
	<keyword>Hydrochlorothiazide</keyword>
</DOC>